Masimo Named One of Fast Company’s Most Innovative Companies in North America

Masimo Named One of Fast Company’s Most Innovative Companies in North America

Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, is thrilled to announce its recognition as one of Fast Company’s Most Innovative Companies in North America for 2024. This prestigious accolade is especially meaningful given Masimo’s notable breakthroughs and the company’s commitment to improve people’s lives through innovation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319317729/en/

Masimo is one of Fast Company's Most Innovative Companies in North America for 2024. (Graphic: Business Wire)

“We are honored to be recognized by Fast Company as one of the top 10 Most Innovative Companies in North America for 2024,” said Joe Kiani, Founder and CEO of Masimo. “This recognizes our ongoing commitment to driving innovation to improve lives. Since our founding 35 years ago, we have made solving what others thought unsolvable our task, and fortunately, thanks to our incredible team, we have solved many ‘unsolvable problems.’ Our solutions have helped improve patient care and reduce the cost of care. We intend to continue to innovate to usher in 22nd century healthcare in this decade.”

Masimo’s inclusion in this respected list highlights its unwavering dedication to innovation and the transformative impact of its technologies in the healthcare sector. Masimo has been recognized as one of the 10 most innovative organizations in the North America sector, a testament to its leadership in advancing patient care through cutting-edge and innovative solutions. In their announcement, Fast Company highlighted several Masimo breakthrough technologies that received FDA clearance in 2023, including Opioid Halo™, an opioid overdose and prevention solution that is the first and only FDA-authorized device to alert you in the event of an opioid overdose; Stork™, a revolutionary baby monitor that provides continuous, accurate monitoring, with alarms, based on Masimo’s foundational pulse oximetry technology; and Masimo W1™, a first-of-its-kind wearable offering accurate, continuous health data and now available both in a consumer sport-oriented version and as a medical watch – the first FDA-cleared watch to provide continuous real-time oxygen saturation and pulse rate for over-the-counter and prescription use.

From its inception, Masimo has been at the forefront of developing innovative monitoring technologies and hospital automation solutions that empower healthcare professionals to make informed decisions and improve patient outcomes. This is why over 200 million people are monitored with Masimo pulse oximeters annually and 9 out of the top 10 hospitals in the United States rely on Masimo SET® pulse oximeters.1-2 Today, Masimo’s portfolio encompasses a wide range of cutting-edge healthcare solutions, including its flagship Signal Extraction Technology® (SET®) pulse oximeter, Bridge™ for opioid withdrawal symptom relief, PerL with Masimo AAT™ for personalized listening, and MightySat® Medical, the first and only FDA-cleared medical fingertip pulse oximeter available over the counter. In addition, Masimo’s most recent consumer products, such as Masimo W1, Stork, and Opioid Halo, provide solutions for continuous and accurate data tracking so individuals can take better control of their health.

Masimo’s innovative solutions have revolutionized patient monitoring and have been instrumental in enhancing clinical decision-making, reducing medical errors, and optimizing healthcare delivery. By continually pushing the boundaries of innovation, Masimo remains at the forefront of transforming healthcare and improving the lives of patients worldwide.

For more information about Masimo and its innovative solutions, please visit www.masimo.com.

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.3 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,4 improve CCHD screening in newborns5 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.6-9 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,1 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.2 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97® and the Masimo W1® medical watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº®, Masimo W1 Sport, and Masimo Stork™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

RPVi has not received FDA 510(k) clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

1. Estimate: Masimo data on file.
2. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
3. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
4. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
5. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
6. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
7. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
8. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
9. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.

Forward-Looking Statements - Masimo

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

About FAST COMPANY

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at www.fastcompany.com.

Masimo
Matt Whewell
720-838-0691
Matt.whewell@masimo.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240319317729/en/